Trial Profile
A 2 week multiple ascending dose, double-blind placebo controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of twice daily administration of oral AEB071 and to explore the pharmacodynamics (PD) of oral AEB071 in moderate to severe psoriasis patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2015
Price :
$35
*
At a glance
- Drugs Sotrastaurin (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 15 Jul 2015 New trial record